Short Interest in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Declines By 38.6%

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) was the target of a significant decrease in short interest during the month of May. As of May 15th, there was short interest totaling 6,068 shares, a decrease of 38.6% from the April 30th total of 9,883 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average trading volume of 5,229 shares, the days-to-cover ratio is currently 1.2 days.

Molecular Partners Price Performance

Molecular Partners stock traded down $0.12 during mid-day trading on Wednesday, hitting $3.80. The company’s stock had a trading volume of 596 shares, compared to its average volume of 4,511. The business has a 50 day moving average price of $4.15 and a 200-day moving average price of $4.33. Molecular Partners has a 12 month low of $3.41 and a 12 month high of $5.36. The stock has a market cap of $153.43 million, a price-to-earnings ratio of -1.96 and a beta of 1.07.

Molecular Partners (NASDAQ:MOLN) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). On average, equities research analysts expect that Molecular Partners will post -1.4 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Molecular Partners in a research note on Friday, April 10th. HC Wainwright reissued a “buy” rating and set a $13.00 price objective on shares of Molecular Partners in a report on Wednesday, April 22nd. Finally, TD Cowen restated a “buy” rating on shares of Molecular Partners in a research report on Monday, March 16th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $8.38.

Institutional Trading of Molecular Partners

A hedge fund recently bought a new stake in Molecular Partners stock. SmartHarvest Portfolios LLC acquired a new stake in shares of Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 12,311 shares of the company’s stock, valued at approximately $54,000. Hedge funds and other institutional investors own 26.55% of the company’s stock.

Molecular Partners Company Profile

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.